SCHEMBL20516548

SCHEMBL20516548

CC(C)(C)OC(=O)n1ccc2nc(Cl)ncc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
POLB P06746 1/20 0.38
PIK3CA P42336 3/20 0.37
PIK3CD O00329 2/20 0.37
ABL1 P00519 2/20 0.37
EGFR P00533 2/20 0.37
HCK P08631 2/20 0.37
SRC P12931 2/20 0.37
KDR P35968 2/20 0.37
PIK3CB P42338 2/20 0.37
MTOR P42345 2/20 0.37
PIK3CG P48736 2/20 0.37
EPHB4 P54760 2/20 0.37
PRKDC P78527 2/20 0.37
PI4KB Q9UBF8 2/20 0.37
MET P08581 2/20 0.37
BUB1 O43683 1/20 0.37
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15091298 0.83 PIK3CA (0.37) HSP90AA1HSP90AB1PIK3CAPIK3CDABL1
SCHEMBL15091451 0.81 HSP90AA1 (0.45) HSP90AA1HSP90AB1POLBPIK3CAPIK3CD
SCHEMBL25053114 0.80 HSP90AA1 (0.44) HSP90AA1HSP90AB1POLBPIK3CAPIK3CD
SCHEMBL25909811 0.78 HSP90AA1 (0.41) HSP90AA1HSP90AB1POLBPIK3CAPIK3CD
SCHEMBL1396849 0.78 PIK3CD (0.48) HSP90AA1HSP90AB1POLBPIK3CAPIK3CD
SCHEMBL17714320 0.78 RPS6KA5 (0.36) EGFRMEN1KMT2AKDM4EALDH1A1
SCHEMBL24400696 0.78 HSP90AA1 (0.43) HSP90AA1HSP90AB1POLBPIK3CAMET
SCHEMBL19949248 0.77 ELANE (0.38) HSP90AA1HSP90AB1POLBEGFRSTK17B
SCHEMBL29913685 0.76 SSTR4 (0.39) HSP90AA1HSP90AB1PIK3CAPIK3CDABL1
SCHEMBL29173101 0.76 SSTR4 (0.39) HSP90AA1HSP90AB1PIK3CAPIK3CDABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291559-A1 PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER Tango Therapeutics, Inc. (US) 2023-12-20 EP disclosed
CN-111511744-B Diazaindole compounds 百时美施贵宝公司 2023-09-22 CN disclosed
WO-2022174184-A1 PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER TANGO THERAPEUTICS, INC. (US) 2022-08-18 WO disclosed
US-11299501-B2 Diazaindole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2022-04-12 US disclosed
EP-3728264-B1 DIAZAINDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-12-01 EP disclosed
EP-3728264-B1 DIAZAINDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-12-01 EP disclosed
EP-3212652-B1 RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIV HEALTH NETWORK (CA) 2021-02-17 EP disclosed
US-10875863-B2 RIPK2 inhibitors and method of treating cancer with same UNIVERSITY HEALTH NETWORK (CA) 2020-12-29 US disclosed
EP-3728264-A1 DIAZAINDOLE COMPOUNDS Bristol-Myers Squibb Company (US) 2020-10-28 EP disclosed
US-20200308195-A1 DIAZAINDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-10-01 US disclosed
US-20200308195-A1 DIAZAINDOLE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-10-01 US disclosed
CN-111511744-A Diazaindole compounds 百时美施贵宝公司 2020-08-07 CN disclosed
US-10239881-B2 RIPK2 inhibitors and method of treating cancer with same UNIVERSITY HEALTH NETWORK (CA) 2019-03-26 US disclosed
US-20180282335-A1 RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2018-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180282335-A1 RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME RIPK2, RIPK1, RIPK4 HSP90AA1 1672/4885HSP90AB1 1409/4885POLB 3409/4885
US-20200308195-A1 DIAZAINDOLE COMPOUNDS TLR7, TLR9, TLR1 HSP90AA1 3699/4885HSP90AB1 3604/4885POLB 3023/4885
US-10875863-B2 RIPK2 inhibitors and method of treating cancer with same RIPK2, RIPK1, RIPK4 HSP90AA1 1673/4885HSP90AB1 1487/4885POLB 3444/4885
US-10239881-B2 RIPK2 inhibitors and method of treating cancer with same RIPK2, RIPK1, RIPK4 HSP90AA1 1672/4885HSP90AB1 1409/4885POLB 3409/4885
US-11299501-B2 Diazaindole compounds TLR7, TLR9, TLR1 HSP90AA1 3699/4885HSP90AB1 3604/4885POLB 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.